NCT00054756 · ADVERSE EVENTS

Adverse events

Study of Thyrotropin-Releasing Hormone in Normal Volunteers and in Patients With Thyroid or Pituitary Abnormalities · Source last updated 2018-08-08

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Adverse events occurred during the study; they are not necessarily caused by treatment. Serious events are not interchangeable with severe/grade 3–4 events. These safety populations may differ from efficacy populations.

Collection time frame: 180 minutes after injection of TRH
Other-event reporting threshold: 5%

Participants affected / participants at risk, as reported
Safety group	Serious events	Other events	Deaths
Thyrotropin Releasing Hormone Subjects receiving TRH (Thyrotropin Releasing Hormone)	0 / 96	0 / 96	0 / 96

Group identifiers: EG000: Thyrotropin Releasing Hormone

Serious adverse events

Event terms and counts are source-reported; expand to read more. A reporting threshold may omit less frequent events.

Other reported adverse events

Event terms and counts are source-reported; expand to read more. A reporting threshold may omit less frequent events.

Complete source fields

event Groups

deaths Num Affected
0
deaths Num At Risk
96
description
Subjects receiving TRH (Thyrotropin Releasing Hormone)
id
EG000
other Num Affected
0
other Num At Risk
96
serious Num Affected
0
serious Num At Risk
96
title
Thyrotropin Releasing Hormone

frequency Threshold

time Frame

180 minutes after injection of TRH

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice